Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
ARQ 501-212
NCT00102700
2.
Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
ARQ 501-221
NCT00310518
3.
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
ARQ 501-208
NCT00358930
4.
ARQ 501 in Subjects With Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
ARQ 501-101
NCT00075933
5.
ARQ 501 in Combination With Docetaxel in Patients With Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
ARQ 501-111
NCT00099190
6.
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Closed
18 and over
Pharmaceutical / Industry
ARQ 501-109
NCT00524524
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute